Nicholas Jackson

Dr. Nicholas Jackson joined Clover Biopharmaceuticals as President of Global R&D. Dr. Jackson has spent over 22 years in vaccine and immunotherapeutic research and development roles, leading multiple successful global programs in bacterial, viral and non-infectious disease targets. In his most recent role with the Centre for Epidemic Preparedness and Innovation (CEPI), Nicholas was the Head of Vaccine Programs and Technology for Research and Development and also served as the Managing Director of CEPI's China office in Shanghai. Prior to his work at CEPI, Dr. Jackson was Vice President, Head of Global Research for Sanofi Pasteur, responsible for leading vaccine research and early development activities globally. Before Sanofi Pasteur, Nicholas held vaccine development and immunotherapeutic roles at Pfizer, IAVI and GlaxoSmithKline, where he oversaw R&D programs, global clinical trials and collaborations.

Dr. Nicholas Jackson holds a Bachelor of Science degree from Oxford Brookes University, a Master of Science from the London School of Hygiene & Tropical Medicine, and a doctorate from the University of Warwick in the field of viral immunology.